MedTrace Logo

Imaging Study of the White Matter Lesions in Children With Metachromatic Leucodystrophy

NCT01325025 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2025-11-20

No results posted yet for this study

Summary

High-field MRI and diffusion tensor imaging with 3D reconstruction of the myelin tracks, in combination with multivoxel proton spectroscopy, will allow to precise more accurately the evolution of the white matter lesions in patients affected with Metachromatic Leukodystrophy (particularly in the initial phase of the disease). This will increase the knowledge of the disease and provide new indicators for the selection and evaluation of patients eligible for new therapeutic approaches.

Conditions

  • Late Infantile Metachromatic Leukodystrophy

Interventions

OTHER

High-field MRI (3 Teslas)

* anatomical location * conventional anatomical sequence T1, T2, FLAIR * diffusion tensor sequence (21 directions) * high angular resolution diffusion (HARDI) sequence * field map * reflexology T1, T2 * spectroscopic imaging sequence

OTHER

High-field MRI (3 Teslas)

* anatomical location * conventional anatomical sequence T1, T2, FLAIR * diffusion tensor sequence (21 directions) * high angular resolution diffusion (HARDI) sequence * field map * reflexology T1, T2 * spectroscopic imaging sequence

Sponsors & Collaborators

  • European Leukodystrophy Association

    collaborator OTHER

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Caroline Sevin, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2016-03-31
Completion
2016-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01325025 on ClinicalTrials.gov